Replies to post #86236 on Biotech Values

[DewDiligence]

IDIX Insider Transactions During Past 24 Months

[Added Standring’s 11/11/09 option exercise.
See #msg-43558454 for current insider holdings.]


OPTION EXERCISES

David Standring, EVP Biology
11-Nov-2009 15,000 options @$1.00 (#msg-43558137)


PURCHASES

Ron Renaud, CFO
11-Mar-2008 15,000 shares @4.50-4.55

Doug Mayers, CMO
11-Mar-2008 30,000 shares @4.45

John Weidenbruch, Gen Counsel
11-Mar-2008 15,000 shares @4.52-4.59


SALES

JP Sommadossi, CEO
*16-Sep-2008 110,000 shares @8.00

*Transfer of shares to University of Alabama as
part of a previously announced legal settlement.


SEC links:
http://sec.gov/Archives/edgar/data/1093649/000120919109052601/xslF345X03/doc4.xml
http://sec.gov/Archives/edgar/data/1093649/000120919108052275/xslF345X03/doc4.xml
http://www.sec.gov/Archives/edgar/data/1093649/000120919108017195/xslF345X02/doc4.xml
http://www.sec.gov/Archives/edgar/data/1093649/000120919108017843/xslF345X02/doc4.xml
http://www.sec.gov/Archives/edgar/data/1093649/000120919108017844/xslF345X02/doc4.xml
http://www.sec.gov/Archives/edgar/data/1093649/000120919106029333/xslF345X02/doc4.xml

[go seek]

following the IDIX story

the ups and downs...
it is of note that insider activity seen in past year or so is more
prevalent than that of earlier years.

IDIX's pipeline is stronger...
it appears IDIX's business strategy will (soon) begin to pay off...